Back

Patients with patent foramen ovale or atrial septal defect have worse outcomes after pulmonary vein isolation

29 August 2025 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Novel insights in catheter ablation of atrial fibrillation Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Mr Sandi Bajrami

Stony Brook (United States of America)

7 More presentations in this session

Presentation thumbnail
Hemolysis biomarkers after pulmonary vein isolation using three different pulsed-field ablation systems
Mr J. Bruegger (Basel, CH)
Abstract Slides Video
Presentation thumbnail
Is catheter ablation in atrial fibrillation patients with functional tricuspid regurgitation as effective as in patients with functional mitral regurgitation?
Doctor Y. Sumiyama (Nishinomiya, JP)
Abstract Slides Video
Presentation thumbnail
Bachmanns bundle related atrial tachycardias following catheter ablation of persistent atrial fibrillation
Doctor N. Christian-Miller (Ann Arbor, US)
Abstract Slides Video
Presentation thumbnail
Pulsed-field ablation versus radiofrequency ablation for paroxysmal atrial fibrillation: a systematic review and meta-analysis
Miss I. Martins Esteves (Porto, PT)
Abstract Slides Video
Presentation thumbnail
31 vs. 35 mm: pulsed-field ablation with two different-sized pentaspline catheters for the treatment of atrial fibrillation
Doctor C. Isenegger (Basel, CH)
Abstract Slides Video

Access the full session

Session thumbnail
Novel insights in catheter ablation of atrial fibrillation

The Event

Event poster

ESC Congress 2025

29 August 2025 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Evidence on efficacy and safety of pulsed field ablation for atrial fibrillation ablation
thumbnail
Congress Presentation
Unsupervised machine learning of multimodal data to identify atrial fibrillation subgroups likely to benefit from pulmonary vein isolation
thumbnail
Congress Presentation
PFO closure: who should get it and how to manage patients medically before, during and after?

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources